{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:10:34Z","timestamp":1792613434262,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinthera.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T20:00:55Z","timestamp":1664913655000},"page":"1432-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States"],"prefix":"10.1016","volume":"44","author":[{"given":"Swapna","family":"Karkare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryia","family":"Zhdanava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail I.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.09.005_bib0001","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2019 National Survey on Drug Use and Health: key substance use and mental health indicators in the United States. Available at: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt29393\/2019NSDUHFFRPDFWHTML\/2019NSDUHFFR090120.htm#mde. Accessed 2020."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0002","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0003","series-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder","first-page":"1","author":"Gelenberg","year":"2010"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2022.09.005_bib0004","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/s40263-012-0031-0","article-title":"Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder","volume":"27","author":"Patkar","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0006","unstructured":"Gaynes BN, Asher G, Gartlehner G, et\u00a0al. Definition of Treatment-Resistant Depression in the Medicare Population. Technology Assessment Program. Project ID: PSYT0816. (Prepared by RTI\u2013UNC Evidence-Based Practice Center under Contract No. HHSA290201500011I_HHSA29032006T.), 2018; 1-115."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0007","unstructured":"US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed June 7, 2021."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0008","series-title":"SPRAVATO\u00ae (esketamine) Prescribing Information","year":"2020"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/da.23138","article-title":"At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: learnings from a population based study","volume":"38","author":"Cepeda","year":"2021","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0012","unstructured":"Massachusetts General Hospital (MGH). Antidepressant Treatment Response Questionnaire (ATRQ), Geriatric Population, version 3. 2016."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0013","unstructured":"Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ), Non-Geriatric Population, version 2. 2015."},{"key":"10.1016\/j.clinthera.2022.09.005_sbref0014","series-title":"Supporting Appropriate Payer Coverage Decisions","year":"2017"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","year":"2013"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0016","unstructured":"Elixhauser A, Steiner C, Kruzikas D. HCUP Comorbidity Software. Healthcare Cost and Utilization Project (HCUP) 2015. Available at: https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download, Last accessed: August 12, 2020."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0017","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0018","unstructured":"U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies REMS. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems. Accessed June 11, 2021."},{"key":"10.1016\/j.clinthera.2022.09.005_bib0019","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40273-021-01042-5","article-title":"Cluster analysis of care pathways in adults with major depressive disorder with acute suicidal ideation or behavior in the USA","volume":"39","author":"Zhdanava","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0021","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4088\/JCP.v65n0406","article-title":"Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report","volume":"65","author":"Husain","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.clinthera.2022.09.005_bib0022","article-title":"Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression","author":"Lihua","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.142.1.1","article-title":"Electroconvulsive therapy and complaints of memory dysfunction: a prospective three-year follow-up study","volume":"142","author":"Squire","year":"1983","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jad.2020.07.014","article-title":"Development of a patient decision aid for treatment resistant depression","volume":"275","author":"Shillington","year":"2020","journal-title":"J Affect Disord"},{"issue":"Suppl 16","key":"10.1016\/j.clinthera.2022.09.005_bib0025","first-page":"S26","article-title":"The burden of disease for treatment-resistant depression","volume":"62","author":"Greden","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0026","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1001\/jama.293.20.2487","article-title":"Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003","volume":"293","author":"Kessler","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0028","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.005_bib0029","series-title":"Health Insurance Coverage in the United States: 2020\u2014Current Population Reports","first-page":"P60","author":"Keisler-Starkey","year":"2021"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:55Z","timestamp":1758963475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0149291822003198"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}